Cite
HARVARD Citation
Buja, A. et al. (2022). Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer. Thoracic cancer. 13 (19), pp. 2692-2698. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Buja, A. et al. (2022). Cost‐effectiveness analysis of the new oncological drug durvalumab in Italian patients with stage III non‐small cell lung cancer. Thoracic cancer. 13 (19), pp. 2692-2698. [Online].